A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...

Aduhelm (aducanumab) and Leqembi are examples of controversial drugs that faced challenges with FDA approval. Learn more about the expensive failure to launch of these medications.

Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer's therapy Aduhelm, handing over full responsibility to its US counterpart.

A Boston College Center for Retirement Research report looks at the financial implications for Medicare of Alzheimer's drug Aduhelm The recent controversy over Alzheimer’s treatment Aduhelm—criticized ...

For Your Patients: Navigating Treatment Options in Early Stage Alzheimer’s Disease — Medications are available to stabilize symptoms and even delay progression ...

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to prescribe Lilly’s amyloid-busting drug.

Bull or Bear, Seeking Alpha is there Markets change, but our community always has the latest in-depth analysis and powerful stock ratings. New! Get unlimited access to breaking stock news—for free.